Drug
Sofosbuvir Ledipasvir Fixed Dose Combination
Sofosbuvir Ledipasvir Fixed Dose Combination: highest development phase Post-Market, developed by Gilead Sciences. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Gilead Sciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC) NCT02858180 | Post-Market | Hepatitis C, Chronic |
Latest
No recent events.
Follow Sofosbuvir Ledipasvir Fixed Dose Combination on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.